Vivos Therapeutics Inc
VVOSHealthcare·Medical Devices·USA·Nano·NASD·Nov 13 • 7:00 AM ET
0.10+0.00 (1.04%)
2026-11-13 13:06 CET
Market cap
$3.26M
Revenue, TTM
20.90 USD m
Net income, TTM
-25.46 USD m
Free cash flow, TTM
-19.01 USD m
EPS diluted, TTM
-2.07
Price
VVOS against its 20, 50 and 200-day averagesPatternshover a marker to name it
96.4% under the 52-week high of 2.69 on 5 Jan 2026. 52-week low 0.09 on 10 Nov 2026. Last 15 sessions, 52.3% high to low
Volume 0.04× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 3 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 3 of 4 — fails: Return on Equity: Over +15%
Quality 0 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Current Ratio: Over 1 — not on the tape: Debt/Equity: Low (<0.1); P/E: Under 25
Value 0 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15; P/B: Under 2; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
VVOS52-week range, 0% of the way up
0.092.69
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.
| Employees | 268 |
|---|---|
| IPO | Dec 11, 2020 |
| Beta | 6.31 |
| ATR, 14d | 0.01 |
| Rel volume | 0.04 |
| Short float | 11.26% |
| Insider own | 18.91% |
| Inst own | 1.93% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $3.26M |
| Enterprise Value | 14.93M |
| Income | -25.46M |
| Sales | 20.90M |
| Book / share | -0.34 |
| Cash / share | 0.05 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 268 |
| IPO | Dec 11, 2020 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 0.16 |
| Price / book | - |
| Price / cash | 1.84 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 0.71 |
| Quick Ratio | 0.21 |
| Current Ratio | 0.21 |
| Debt / equity | - |
| Long-term debt / equity | - |
| Options and short | No / Yes |
Earnings
| Earnings / share | -2.07 |
|---|---|
| Earnings next year | -0.10 |
| Earnings next quarter | -0.30 |
| Earnings this year | 37.20% |
| Earnings next year | 92.31% |
| Earnings growth, 5 years | - |
| Past earnings growth | 56.99% 39.15% |
| Past sales growth | 2.87% 5.95% |
| Earnings vs last year | -10.29% |
| Sales vs last year | 45.21% |
| Earnings vs last quarter | 43.80% |
| Sales vs last quarter | 34.90% |
| Earnings | Aug 14 AMC |
| Surprise | 24.39% -8.53% |
Ownership
| Insiders own | 18.91% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 1.93% |
| Institution trades | -4.86% |
| Return on assets | -101.47% |
| Return on equity | -6629.43% |
| Return on capital | -35356.94% |
| Gross Margin | 53.33% |
| Operating margin | -107.92% |
| Profit Margin | -121.80% |
| 20-day average | -15.03% |
| 50-day average | -30.33% |
| 200-day average | -85.21% |
Technical
| Shares out | 33.61M |
|---|---|
| Shares floating | 27.25M |
| Short / float | 11.26% |
| Short ratio | 0.22 |
| Short interest | 3.07M |
| 52-week high | 2.69 -96.4% |
| 52-week low | 0.09 +12.8% |
| Volatility | 11.25% 9.84% |
| Average range | 0.01 |
| Strength index | 32.27 |
| Market sensitivity | 6.31 |
| Relative volume | 0.04 |
| Avg Volume | 14.06M |
| Volume | 27,336 |
Performance
| Perf Week | 3.52% |
|---|---|
| Perf Month | -32.07% |
| Perf Quarter | -67.80% |
| Perf Half Y | -84.87% |
| Perf YTD | -95.22% |
| Perf Year | -95.99% |
| Perf 3Y | -97.15% |
| Perf 5Y | -99.90% |
| Perf 10Y | - |
| Recommendation | 3.00 |
| Target Price | 0.75 |
| Prev Close | 0.10 |
| Price | 0.10 |
| Change % | 1.36% |
Peers
Mkt capInsider trading
1 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Skaff Michael C | 10% Owner | Mar 31 '26 | Buy | 1.34 | 1,353,625 | 1,813,858 | 1,353,625 | Apr 02 07:34 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
News
latest 14 of 196- Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard (GlobeNewswire)
- Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel (GlobeNewswire)
- Vivos to buy 50% stake in SOD Sciences pseudohypoxia test (Medical Device Network) -8.19%
- Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test (GlobeNewswire) +6.57%
- Vivos Therapeutics Targets $3.6 Million in Annual Cost Reductions as Revenue Growth Initiatives Accelerate (InvestorsHub) +12.23%
- Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives (GlobeNewswire)
- Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference (Newsfile) -13.98%
- Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center (GlobeNewswire) -12.96%
- Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers (GlobeNewswire)
- Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment (GlobeNewswire)
- Vivos Therapeutics Inc (VVOS) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% on ... (GuruFocus.com) -6.29%
- Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts (InvestorsHub) -12.26%
- Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire) +12.45%
- Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call (GlobeNewswire)
Quarterly earnings
2026Q2 EPS -0.310 beat -0.410, from -0.550 a year earlier. Sales 5.15 missed 5.63, from 3.82 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-08-14 16:30 | -0.310 | -0.410 | - | 5.15 | 5.63 | EPS -24.4% · sales -8.5% | vs 2025Q2, year-ago quarter · EPS -43.6% · sales +34.9% | 3 | Open -11.16% vs SPY -0.02%. Close -12.26% vs SPY -0.47% |
| 2026Q1ended 2026-03-31 | 2026-05-20 16:30 | -0.520 | -0.453 | -0.525 | 5.14 | 4.35 | EPS +14.7% · sales +18.2% | vs 2025Q1, year-ago quarter · EPS +15.6% · sales +70.5% | 3 EPS · 4 sales | Open -1.69% vs SPY -0.35%. Close -0.88% vs SPY +0.20% |
| 2025Q4ended 2025-12-31 | 2026-04-15 16:30 | -0.580 | -0.495 | -0.742 | 3.82 | 7.10 | EPS +17.2% · sales -46.1% | vs 2024Q4, year-ago quarter · EPS -241.5% · sales +3.3% | 2 EPS · 3 sales | Open -15.65% vs SPY +0.16%. Close -25.85% vs SPY +0.25% |
| 2025Q3ended 2025-09-30 | 2025-11-19 16:30 | -0.490 | -0.510 | -0.493 | 6.78 | 4.71 | EPS -3.9% · sales +43.9% | vs 2024Q3, year-ago quarter · EPS +22.5% · sales +73.9% | 3 EPS · 4 sales | Open -4.24% vs SPY +1.55%. Close -10.17% vs SPY -1.52% |
| 2025Q2ended 2025-06-30 | 2025-08-19 16:30 | -0.550 | -0.380 | -0.552 | 3.82 | 3.36 | EPS +44.7% · sales +13.5% | vs 2024Q2, year-ago quarter · EPS -8.3% · sales -5.8% | 1 | Open -3.98% vs SPY -0.06%. Close -3.28% vs SPY -0.27% |
| 2025Q1ended 2025-03-31 | 2025-05-15 16:30 | -0.450 | -0.400 | -0.450 | 3.02 | 3.67 | EPS +12.5% · sales -17.7% | vs 2024Q1, year-ago quarter · EPS -72.4% · sales -11.8% | 2 | Open -5.23% vs SPY +0.13%. Close -16.99% vs SPY +0.63% |
| 2024Q4ended 2024-12-31 | 2025-03-31 16:30 | 0.410 | -0.395 | -0.480 | 3.70 | 3.89 | EPS -203.8% · sales -4.7% | vs 2023Q4, year-ago quarter · EPS -113.1% · sales +15.7% | 2 | Open -1.05% vs SPY -0.35%. Close -7.72% vs SPY +0.28% |
| 2024Q3ended 2024-09-30 | 2024-11-14 16:30 | -0.400 | -0.655 | -0.396 | 3.90 | 4.18 | EPS -38.9% · sales -6.7% | vs 2023Q3, year-ago quarter · EPS -77.1% · sales +18.1% | 2 | Open +0.96% vs SPY -0.61%. Close -8.97% vs SPY -1.28% |
| 2024Q2ended 2024-06-30 | 2024-08-14 16:30 | -0.600 | -1.050 | -0.598 | 4.05 | 3.60 | EPS -42.9% · sales +12.6% | vs 2023Q2, year-ago quarter · EPS -86.7% · sales +19.2% | 1 | Open +4.22% vs SPY +1.06%. Close -5.11% vs SPY +1.71% |
| 2024Q1ended 2024-03-31 | 2024-05-14 16:30 | -1.630 | -1.175 | -1.630 | 3.42 | 3.41 | EPS +38.7% · sales +0.3% | vs 2023Q1, year-ago quarter · EPS -6.9% · sales -11.4% | 2 | Open -14.46% vs SPY +0.48%. Close -12.45% vs SPY +1.24% |
| 2023Q4ended 2023-12-31 | 2024-03-28 16:30 | -3.140 | -1.905 | -2.322 | 3.20 | 3.41 | EPS +64.8% · sales -6.0% | vs 2022Q4, year-ago quarter · EPS -33.9% · sales -22.6% | 2 | Open -22.36% vs SPY +0.15%. Close -30.23% vs SPY -0.17% |
| 2023Q3ended 2023-09-30 | 2023-11-14 16:30 | -1.750 | -3.000 | -1.748 | 3.30 | 4.50 | EPS -41.7% · sales -26.6% | vs 2022Q3, year-ago quarter · EPS -73.1% · sales -22.3% | 1 | Open +5.90% vs SPY +0.31%. Close +3.22% vs SPY +0.21% |
| 2023Q2ended 2023-06-30 | 2023-08-16 16:30 | -4.500 | -3.625 | -4.618 | 3.40 | 4.12 | EPS +24.1% · sales -17.4% | - | 2 | - |
| 2023Q1ended 2023-03-31 | 2023-06-08 16:30 | -1.750 | -4.500 | -1.719 | 3.86 | 4.01 | EPS -61.1% · sales -3.7% | vs 2022Q1, year-ago quarter · EPS -73.1% · sales +11.5% | 2 | - |
| 2022Q4ended 2022-12-31 | 2023-03-30 16:30 | -4.750 | -5.500 | -6.615 | 4.13 | 4.55 | EPS -13.6% · sales -9.2% | vs 2021Q4, year-ago quarter · EPS -40.6% · sales -6.0% | 2 | - |
| 2022Q3ended 2022-09-30 | 2022-12-20 16:30 | -6.500 | - | -6.398 | 4.25 | - | EPS - · sales - | vs 2021Q3, year-ago quarter · EPS 0.0% · sales -6.6% | - | - |
Annual earnings
2025FY EPS -2.070 missed -1.950, from -2.220 a year earlier. Sales 17.44 missed 20.71, from 15.03 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2027FYestimate | - | -0.100 | - | - | 45.08 | - |
| 2026FYestimate | - | -1.300 | - | - | 21.79 | - |
| 2025FY | -2.070 | -1.950 | - | 17.44 | 20.71 | - |
| 2024FY | -2.220 | -2.020 | -2.218 | 15.03 | 15.20 | - |
| 2023FY | -11.140 | -10.515 | -11.139 | 13.80 | 13.98 | - |
| 2022FY | -26.000 | -26.500 | -25.905 | 16.02 | 16.55 | - |
| 2021FY | -24.000 | -22.500 | -23.887 | 16.89 | 17.30 | - |
| 2020FY | -25.875 | -15.000 | -24.696 | 13.08 | 12.94 | - |
Quarterly results
2026Q2 revenue 5.15, from 3.82 a year earlier. Operating margin -93.8%, from -127.49% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -1.30 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-01 | -1.30 | 0.0% |
| 2026FY | S | per share | 2026-11-01 | 21.79 | 0.0% |
| 2026Q3 | S | per share | 2026-11-01 | 5.48 | 0.0% |
| 2026Q3 | E | per share | 2026-10-15 | -0.30 | +42.9% |
| 2026Q2 | S | per share | 2026-08-09 | 5.63 | 0.0% |
| 2026Q2 | E | per share | 2026-07-25 | -0.41 | +5.1% |
| 2026Q1 | E | per share | 2026-04-21 | -0.45 | -5.6% |
| 2026Q1 | S | per share | 2026-04-21 | 4.35 | +1.2% |
| 2025FY | E | per share | 2026-03-30 | -1.95 | 0.0% |
| 2025Q4 | E | per share | 2026-03-30 | -0.46 | 0.0% |
| 2025FY | S | per share | 2026-03-30 | 20.61 | 0.0% |
| 2025Q4 | S | per share | 2026-03-30 | 7.00 | 0.0% |
| 2025Q3 | E | per share | 2025-11-14 | -0.51 | +4.1% |
| 2025Q3 | S | per share | 2025-11-14 | 4.71 | -4.8% |
| 2025Q2 | E | per share | 2025-08-02 | -0.38 | 0.0% |
| 2025Q2 | S | per share | 2025-08-02 | 3.36 | 0.0% |
| 2025Q1 | E | per share | 2025-04-11 | -0.40 | +11.1% |
| 2025Q1 | S | per share | 2025-04-11 | 3.67 | +0.9% |
| 2024FY | E | per share | 2025-02-01 | -2.02 | 0.0% |
| 2024Q4 | E | per share | 2025-02-01 | -0.40 | 0.0% |
| 2024FY | S | per share | 2025-02-01 | 15.20 | 0.0% |
| 2024Q4 | S | per share | 2025-02-01 | 3.89 | 0.0% |
| 2024Q3 | E | per share | 2024-10-30 | -0.66 | 0.0% |
| 2024Q3 | S | per share | 2024-10-30 | 4.18 | 0.0% |
| 2024Q2 | S | per share | 2024-07-31 | 3.60 | 0.0% |
| 2024Q2 | E | per share | 2024-06-08 | -1.05 | 0.0% |
| 2024Q1 | E | per share | 2024-04-08 | -1.18 | -1.3% |
| 2024Q1 | S | per share | 2024-04-08 | 3.41 | +2.7% |
| 2023FY | E | per share | 2024-02-22 | -10.52 | -8.4% |
| 2023FY | S | per share | 2024-02-22 | 13.98 | -1.5% |
Estimate history
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -12.972 | -16.154 | -24.696 | -23.887 | -25.905 | -11.139 | -2.218 | -2.061 | -2.0698 | - |
| Sales USD millions | 4 | 11 | 13 | 17 | 16 | 14 | 15 | 17 | 21 | - |
| Shares million shares | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 9 | - | 15 |
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.598 | -0.396 | -0.48 | -0.45 | -0.552 | -0.493 | -0.742 | -0.525 | -0.31 |
| Sales USD millions | 4 | 4 | 4 | 3 | 4 | 7 | 4 | 5 | 5 |
| Shares million shares | 3 | 5 | 6 | 6 | 7 | 8 | 9 | 13 | 15 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 20.90 | 17.44+16.0% | 15.03+8.9% | 13.80-13.9% | 16.02-5.2% | 16.89+29.2% | 13.07+14.7% | 11.39+200.5% | 3.79 |
| Cost of Goods Sold Incl. D&A | 9.75 | 8.21+24.6% | 6.59+7.2% | 6.15-7.8% | 6.67+33.1% | 5.01+48.7% | 3.37-3.4% | 3.49+106.5% | 1.69 |
| Gross Profit | 11.15 | 9.23+9.4% | 8.44+10.3% | 7.65-18.2% | 9.35-21.2% | 11.87+22.5% | 9.69+22.5% | 7.91+276.7% | 2.10 |
| Selling, General and Administrative Excl. Other | 33.70 | 29.13+48.5% | 19.61-21.4% | 24.95-27.4% | 34.38+9.7% | 31.34+70.3% | 18.40-0.4% | 18.48+77.0% | 10.44 |
| Research and Development | - | 0.100.0% | 0.100.0% | 0.10 | - | - | - | - | - |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -22.56 | -19.89 | -11.17 | -17.30 | -25.03 | -19.47 | -8.71 | -10.58 | -8.34 |
| Interest Expense | - | - | 0.00 | 0.00 | 0.00-100.0% | 0.01-90.0% | 0.10-28.6% | 0.14+40.0% | 0.10 |
| Unusual Expense | -0.30 | 0.00 | 0.00 | -3.78 | -1.29-241.8% | 0.91-72.7% | 3.33 | 0.00 | 0.00 |
| Net Income Before Taxes | -25.63 | -21.23 | -11.14 | -13.58 | -23.84 | -20.29 | -12.06 | -10.75 | -8.44 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -25.63 | -21.23 | -11.14 | -13.58 | -23.84 | -20.29 | -15.65 | -10.75 | -8.44 |
| Net Income From Continuing Operations | -25.46 | -21.17 | -11.14 | -13.58 | -23.84 | -20.29 | -15.65 | -10.75 | -8.44 |
| Net Income | -25.46 | -21.17 | -11.14 | -13.58 | -23.84 | -20.29 | -17.99 | -11.75 | -9.44 |
| EPS (Recurring) per share | -1.45 | -2.06 | -2.22 | -13.31 | -26.88 | -23.14 | -21.49 | -16.15 | -12.97 |
| EPS (Basic, Before Extraordinaries) per share | -2.07 | -2.06 | -2.22 | -11.14 | -25.90 | -23.89 | -24.70 | -16.15 | -12.97 |
| EPS (Diluted) per share | -2.07 | -2.06 | -2.22 | -11.14 | -25.90 | -23.89 | -24.70 | -16.15 | -12.97 |
| EBITDA | -20.77 | -18.59 | -10.59 | -16.68 | -24.36 | -18.74 | -7.99 | -9.83 | -7.73 |
| Non-Operating Income (Expense) | -2.27 | -1.34-3450.0% | 0.04 | -0.07 | -0.10-190.9% | 0.11+37.5% | 0.08 | -0.04 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.60 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.30 | 0.66-13.2% | 0.76-31.5% | 1.11-53.7% | 2.40-9.8% | 2.66+22.6% | 2.17+9.0% | 1.99+55.5% | 1.28 |
| Price To Sales Ratio ratio | 0.38 | 1.20 | 1.43 | 1.10 | 0.58 | 2.83 | 8.24 | - | - |
| Gross Margin % | 53.33 | 52.93 | 56.14 | 55.43 | 58.35 | 70.31 | 74.20 | 69.39 | 55.37 |
| Operating Margin % | -107.92 | -114.05 | -74.32 | -125.32 | -156.21 | -115.32 | -66.65 | -92.84 | -219.82 |
| Net Margin % | -121.80 | -121.37 | -74.09 | -98.42 | -148.81 | -120.15 | -137.67 | -103.17 | -248.91 |
| Shares Outstanding million shares | 14.53 | 9.29+57.7% | 5.89+221.9% | 1.83+98.9% | 0.920.0% | 0.92+26.0% | 0.730.0% | 0.730.0% | 0.73 |
| Market Capitalization | 3.22 | 3.22-84.5% | 20.74+25.2% | 16.57+79.1% | 9.25-82.1% | 51.78-51.9% | 107.62-3.0% | 110.97 | - |
Income statement, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5.15+34.8% | 5.14+70.2% | 3.82+3.2% | 6.78+75.6% | 3.82-5.7% | 3.02-11.7% | 3.70+13.8% | 3.86+17.0% |
| Cost of Goods Sold Incl. D&A | 2.71+34.2% | 2.54+51.2% | 1.28-26.9% | 3.23+93.4% | 2.02+30.3% | 1.68+3.1% | 1.75+19.9% | 1.67+7.7% |
| Gross Profit | 2.44+35.6% | 2.60+95.5% | 2.55+30.8% | 3.55+62.1% | 1.80-28.3% | 1.33-25.7% | 1.95+8.9% | 2.19+25.1% |
| Selling, General and Administrative Excl. Other | 7.27+9.0% | 9.22+75.6% | 8.93+87.6% | 8.29+71.6% | 6.67+50.2% | 5.25-5.9% | 4.76-21.6% | 4.83-7.8% |
| Research and Development | - | - | - | - | - | - | - | 0.00-100.0% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.83 | -6.62 | -6.38 | -4.73 | -4.87 | -3.92 | -2.81 | -2.65 |
| Interest Expense | 1.10 | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Unusual Expense | -0.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -5.52 | -7.75 | -6.95 | -5.40 | -5.01 | -3.86 | -2.83 | -2.62 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -5.52 | -7.75 | -6.95 | -5.40 | -5.01 | -3.86 | -2.83 | -2.62 |
| Net Income From Continuing Operations | -5.48 | -7.68 | -6.89 | -5.40 | -5.01 | -3.86 | -2.83 | -2.62 |
| Net Income | -5.48 | -7.68 | -6.89 | -5.40 | -5.01 | -3.86 | -2.83 | -2.62 |
| EPS (Recurring) per share | -0.32 | -0.52 | -0.74 | -0.49 | -0.55 | -0.45 | -0.48 | -0.40 |
| EPS (Basic, Before Extraordinaries) per share | -0.31 | -0.52 | -0.74 | -0.49 | -0.55 | -0.45 | -0.48 | -0.40 |
| EPS (Diluted) per share | -0.31 | -0.52 | -0.74 | -0.49 | -0.55 | -0.45 | -0.48 | -0.40 |
| EBITDA | -4.32 | -6.16 | -5.94 | -4.35 | -4.56 | -3.74 | -2.66 | -2.50 |
| Non-Operating Income (Expense) | 0.10 | -1.14-2380.0% | -0.57 | -0.67-2333.3% | -0.15-1600.0% | 0.05+150.0% | -0.02-300.0% | 0.03 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.05 | 0.15 | 0.05-16.7% | 0.06-57.1% | - | 0.00-100.0% | 0.06-60.0% | 0.14-26.3% |
| Price To Sales Ratio ratio | 0.38 | 0.88 | 1.08 | 1.96 | 1.99 | 1.67 | 1.68 | 1.18 |
| Gross Margin % | 47.41 | 50.67 | 66.58 | 52.38 | 47.23 | 44.16 | 52.81 | 56.68 |
| Operating Margin % | -93.63 | -128.67 | -166.89 | -69.79 | -127.36 | -129.91 | -75.88 | -68.52 |
| Net Margin % | -106.37 | -149.43 | -180.28 | -79.61 | -131.23 | -128.12 | -76.45 | -67.77 |
| Shares Outstanding million shares | 14.53+98.5% | 13.49+129.0% | 9.29+57.7% | 8.27+73.4% | 7.32+115.3% | 5.89+115.8% | 5.89+221.9% | 4.77+297.5% |
| Market Capitalization | 3.22-82.7% | 12.35-26.4% | 18.25-12.0% | 23.26+87.0% | 18.61+146.8% | 16.79+161.1% | 20.74+25.2% | 12.44+116.3% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 2.03-67.6% | 6.26+281.7% | 1.64-53.4% | 3.52-85.4% | 24.03+32.0% | 18.21+3774.5% | 0.47-62.4% | 1.25 |
| Short Term Receivables | 1.58+267.4% | 0.43+115.0% | 0.20-56.5% | 0.46-73.3% | 1.72+13.2% | 1.52+58.3% | 0.96+60.0% | 0.60 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.77-1.3% | 0.78+25.8% | 0.62-57.2% | 1.45-7.6% | 1.57+134.3% | 0.67+123.3% | 0.30+900.0% | 0.03 |
| Total Current Assets | 4.38-41.4% | 7.47+203.7% | 2.46-54.6% | 5.42-80.2% | 27.32+34.0% | 20.39+1085.5% | 1.72-8.5% | 1.88 |
| Net Property, Plant & Equipment | 7.92+80.8% | 4.38-6.8% | 4.70-1.7% | 4.78+68.9% | 2.83+225.3% | 0.87-23.7% | 1.14-10.9% | 1.28 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Note Receivable | - | - | - | - | 0.00-100.0% | 0.81+2.5% | 0.79 | 0.00 |
| Intangible Assets | 12.62+293.1% | 3.21-1.5% | 3.26+3.5% | 3.15-0.9% | 3.18+8.2% | 2.94-12.5% | 3.36-31.1% | 4.88 |
| Other Assets | 0.23+4.5% | 0.22-29.0% | 0.31-16.2% | 0.37+2.8% | 0.36+16.1% | 0.31-43.6% | 0.55+243.8% | 0.16 |
| Total Assets | 25.15+64.6% | 15.28+42.4% | 10.73-21.8% | 13.72-59.3% | 33.69+33.0% | 25.33+235.5% | 7.55-7.9% | 8.20 |
| Short Term Debt Incl. Current Port. of LT Debt | 9.08+1791.7% | 0.48+2.1% | 0.47+11.9% | 0.42-66.7% | 1.26+44.8% | 0.87-76.5% | 3.71+2218.8% | 0.16 |
| Accounts Payable | 1.68+52.7% | 1.10-48.8% | 2.15+52.5% | 1.41+53.3% | 0.92-59.6% | 2.28+111.1% | 1.08+129.8% | 0.47 |
| Other Current Liabilities | 7.32+115.3% | 3.40-27.2% | 4.67-6.2% | 4.98-6.4% | 5.32+13.9% | 4.67+8.6% | 4.30+182.9% | 1.52 |
| Total Current Liabilities | 18.08+263.1% | 4.98-31.7% | 7.29+7.0% | 6.81-9.3% | 7.51-4.0% | 7.82-14.0% | 9.09+320.8% | 2.16 |
| Long Term Debt | 4.42+329.1% | 1.03-32.2% | 1.52-23.6% | 1.99 | 0.00-100.0% | 0.42 | 0.00-100.0% | 0.53 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 4.20+218.2% | 1.32-12.6% | 1.51+1272.7% | 0.11-82.8% | 0.64+300.0% | 0.16+100.0% | 0.08+166.7% | 0.03 |
| Total Liabilities | 26.70+264.3% | 7.33-29.0% | 10.32+15.7% | 8.92+9.4% | 8.15-3.1% | 8.41-8.4% | 9.18+238.7% | 2.71 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.32+97.0% | 0.67 |
| Common Equity | -1.49-118.7% | 7.95+1839.0% | 0.41-91.5% | 4.80-81.2% | 25.54+50.9% | 16.92 | -2.94-160.9% | 4.83 |
| Total Shareholders Equity | -1.49-118.7% | 7.95+1839.0% | 0.41-91.5% | 4.80-81.2% | 25.54+50.9% | 16.92 | -1.63-129.7% | 5.49 |
| Accumulated Minority Interest | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -1.55-119.5% | 7.95+1839.0% | 0.41-91.5% | 4.80-81.2% | 25.54+50.9% | 16.92 | -1.63-129.7% | 5.49 |
| Total Liabilities & Stockholders Equity | 25.15+64.6% | 15.28+42.4% | 10.73-21.8% | 13.72-59.3% | 33.69+33.0% | 25.33+235.5% | 7.55-7.9% | 8.20 |
| Book Value Per Share per share | -0.16-111.9% | 1.35+513.6% | 0.22-95.8% | 5.22-81.2% | 27.75+19.5% | 23.23 | -4.04-160.9% | 6.63 |
| Tangible Book Value Per Share per share | -1.52-290.0% | 0.80 | -1.56-186.7% | 1.80-92.6% | 24.29+26.6% | 19.19 | -8.66 | -0.08 |
| Full-Time Employees people | 268+145.9% | 109-4.4% | 114-26.0% | 154-2.5% | 158+61.2% | 98 | - | - |
| Price to Book Ratio ratio | -0.28 | 2.67 | 323.79 | 0.94 | 2.03 | 6.36 | -16.07 | - |
| Return on Assets % | -104.71 | -85.62 | -111.11 | -100.59 | -68.75 | -95.22 | -136.52 | - |
| Return on Equity % | -655.01 | -266.25 | -521.22 | -157.19 | -95.57 | -204.75 | -556.20 | - |
| Return on Invested Capital % | -722.03 | -123.88 | -703.05 | -350.92 | -79.44 | -90.28 | - | -140.22 |
| Quick Ratio ratio | 0.24 | 1.50 | 0.34 | 0.80 | 3.64 | 2.61 | 0.19 | 0.87 |
| Current Ratio ratio | 0.24 | 1.50 | 0.34 | 0.80 | 3.64 | 2.61 | 0.19 | 0.87 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -25.63 | -21.23 | -11.14 | -13.58 | -23.84 | -20.29 | -12.06 | -10.75 | -8.44 |
| Depreciation | 1.79 | 1.31+125.9% | 0.58-6.5% | 0.62-7.5% | 0.67-8.2% | 0.73+1.4% | 0.72-4.0% | 0.75+23.0% | 0.61 |
| Other Funds (Non Cash) | 0.79 | 0.66-17.5% | 0.80 | -1.85-198.4% | 1.88-50.4% | 3.79-37.8% | 6.09+185.9% | 2.13+38.3% | 1.54 |
| Funds from Operations | -23.05 | -19.26 | -9.75 | -14.81 | -21.30 | -15.76 | -5.25 | -7.87 | -6.28 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 5.92 | 4.00 | -2.94-202.8% | 2.86+67.3% | 1.71+5600.0% | 0.03 | -0.43-117.0% | 2.53+190.8% | 0.87 |
| Cash from Operating Activities | -17.13 | -15.26 | -12.69 | -11.95 | -19.59 | -15.73 | -5.68 | -5.34 | -5.42 |
| Capital Expenditures | -1.88 | -2.34 | -0.57 | -0.85 | -0.92 | -2.40 | -0.12 | -0.18 | -1.25 |
| Net Assets From Acquisitions | -0.05 | -5.18 | 0.00 | 0.00 | 0.00 | -0.23 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.25+92.3% | 0.13 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.01 | 0.00-100.0% | 0.01 | 0.00 |
| Cash from Investing Activities | -1.93 | -7.53 | -0.57 | -0.85 | -0.92 | -2.61 | -0.12-233.3% | 0.09 | -1.12 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 13.65 | 7.91-55.8% | 17.88+63.7% | 10.92 | 0.00-100.0% | 24.19+7.1% | 22.59+2410.0% | 0.90-83.5% | 5.45 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.50 | -2.15 | -0.35 | -1.00 |
| Sale of Common Pref Stock | 13.65 | 7.91-55.8% | 17.88+63.7% | 10.92 | 0.00-100.0% | 25.69+3.8% | 24.74+1879.2% | 1.25-80.6% | 6.45 |
| Proceedsfrom Stock Options | 10.30 | 6.44+0.2% | 6.43 | -1.08 | 0.00-100.0% | 25.69+3.8% | 24.74+1879.2% | 1.25-80.6% | 6.45 |
| Issuance or Reduction of Debt, Net | 2.78 | 10.64 | 0.00 | 0.00 | 0.00 | -0.03-103.2% | 0.94-73.7% | 3.57 | -0.09 |
| Change in Long Term Debt | 2.78 | 10.64 | 0.00 | 0.00 | 0.00 | -0.03-103.2% | 0.94-73.7% | 3.57 | -0.09 |
| Issuance of Long Term Debt | 4.06 | 10.67 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.02-71.7% | 3.60 | 0.00 |
| Reduction of Long Term Debt | -1.28 | -0.03 | 0.00 | 0.00 | 0.00 | -0.03 | -0.07 | -0.03 | -0.09 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 16.43 | 18.56+3.8% | 17.88+63.7% | 10.92 | 0.00-100.0% | 24.17+2.7% | 23.54+426.6% | 4.47-16.6% | 5.36 |
| Net Change in Cash | -2.63 | -4.23-191.6% | 4.62 | -1.88 | -20.51-452.4% | 5.82-67.2% | 17.74 | -0.79 | -1.18 |
| Free Cash Flow | -19.01 | -17.60 | -13.26 | -12.75 | -20.51 | -18.13 | -5.80 | -5.52 | -6.67 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 1.77-59.8% | 2.11-9.8% | 2.03-67.6% | 3.09-51.0% | 4.40-36.2% | 2.34-10.3% | 6.26+281.7% | 6.31+537.4% |
| Short Term Receivables | 1.44-11.7% | 1.77+145.8% | 1.58+267.4% | 2.13+373.3% | 1.63+307.5% | 0.72+35.8% | 0.43+115.0% | 0.45+95.7% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.00+44.9% | 0.94+70.9% | 0.77-1.3% | 0.56-11.1% | 0.69+25.5% | 0.55+17.0% | 0.78+25.8% | 0.63-18.2% |
| Total Current Assets | 4.21-37.4% | 4.82+33.5% | 4.38-41.4% | 5.79-21.8% | 6.73-14.3% | 3.610.0% | 7.47+203.7% | 7.40+271.9% |
| Net Property, Plant & Equipment | 7.45-11.0% | 7.56+77.5% | 7.92+80.8% | 9.03+102.9% | 8.37+86.8% | 4.26-8.0% | 4.38-6.8% | 4.45-6.3% |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 12.21+14.3% | 12.41+287.8% | 12.62+293.1% | 10.62+228.8% | 10.68+229.6% | 3.20-1.5% | 3.21-1.5% | 3.23-1.5% |
| Other Assets | 0.27+3.8% | 0.25+19.0% | 0.23+4.5% | 0.21-25.0% | 0.26-7.1% | 0.21-32.3% | 0.22-29.0% | 0.28-9.7% |
| Total Assets | 24.14-7.3% | 25.04+122.0% | 25.15+64.6% | 25.64+67.0% | 26.03+64.3% | 11.28-4.4% | 15.28+42.4% | 15.35+48.7% |
| Short Term Debt Incl. Current Port. of LT Debt | 8.62+890.8% | 8.10+1623.4% | 9.08+1791.7% | 1.13+135.4% | 0.87+81.3% | 0.47-2.1% | 0.48+2.1% | 0.48+4.3% |
| Accounts Payable | 2.95+67.6% | 2.00+65.3% | 1.68+52.7% | 2.10+96.3% | 1.76-13.3% | 1.21-51.6% | 1.10-48.8% | 1.07-30.1% |
| Other Current Liabilities | 8.82+132.1% | 7.84+158.7% | 7.32+115.3% | 4.21+17.9% | 3.80-8.0% | 3.03-40.5% | 3.40-27.2% | 3.57-31.1% |
| Total Current Liabilities | 20.39+217.1% | 17.94+281.7% | 18.08+263.1% | 7.44+45.0% | 6.43-3.2% | 4.70-41.8% | 4.98-31.7% | 5.13-28.5% |
| Long Term Debt | 3.89-63.7% | 4.17+348.4% | 4.42+329.1% | 11.37+880.2% | 10.71+736.7% | 0.93-33.6% | 1.03-32.2% | 1.16-29.3% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 3.85-10.7% | 4.20+238.7% | 4.20+218.2% | 4.30+207.1% | 4.31+174.5% | 1.24-29.1% | 1.32-12.6% | 1.40-4.1% |
| Total Liabilities | 28.13+31.1% | 26.31+282.4% | 26.70+264.3% | 23.11+200.9% | 21.45+126.0% | 6.88-38.7% | 7.33-29.0% | 7.68-25.2% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 1.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -4.92-207.4% | -1.14-125.9% | -1.49-118.7% | 2.53-67.0% | 4.58-27.9% | 4.41+660.3% | 7.95+1839.0% | 7.67+15240.0% |
| Total Shareholders Equity | -3.81-183.2% | -1.14-125.9% | -1.49-118.7% | 2.53-67.0% | 4.58-27.9% | 4.41+660.3% | 7.95+1839.0% | 7.67+15240.0% |
| Accumulated Minority Interest | -0.17 | -0.13 | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -3.99-187.1% | -1.27-128.8% | -1.55-119.5% | 2.53-67.0% | 4.58-27.9% | 4.41+660.3% | 7.95+1839.0% | 7.67+15240.0% |
| Total Liabilities & Stockholders Equity | 24.14-7.3% | 25.04+122.0% | 25.15+64.6% | 25.64+67.0% | 26.03+64.3% | 11.28-4.4% | 15.28+42.4% | 15.35+48.7% |
| Book Value Per Share per share | -0.34-154.0% | -0.08-110.7% | -0.16-111.9% | 0.31-80.7% | 0.63-66.3% | 0.75+257.1% | 1.35+513.6% | 1.61+3925.0% |
| Tangible Book Value Per Share per share | -1.18 | -1.00-600.0% | -1.52-290.0% | -0.98-205.4% | -0.83-191.2% | 0.20 | 0.80 | 0.93 |
| Full-Time Employees people | - | 268 | 268+145.9% | - | - | - | 109-4.4% | - |
| Price to Book Ratio ratio | -0.28 | 3.85 | 6.63 | 4.95 | 4.22 | 2.11 | 2.67 | 1.40 |
| Return on Assets % | -101.47 | -137.59 | -104.71 | -83.45 | -68.39 | -97.35 | -85.62 | -97.94 |
| Return on Equity % | -6,629.43 | -1,528.85 | -655.04 | -335.47 | -262.03 | -450.47 | -266.25 | -325.98 |
| Return on Invested Capital % | -7,612.50 | -253.45 | -235.13 | -38.84 | -32.77 | -72.37 | -31.45 | -29.65 |
| Quick Ratio ratio | 0.21 | 0.27 | 0.24 | 0.78 | 1.05 | 0.77 | 1.50 | 1.44 |
| Current Ratio ratio | 0.21 | 0.27 | 0.24 | 0.78 | 1.05 | 0.77 | 1.50 | 1.44 |
Cash flow, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -5.52 | -7.75 | -6.95 | -5.40 | -5.01 | -3.86 | -2.83 | -2.62 |
| Depreciation | 0.51+64.5% | 0.45+150.0% | 0.44+214.3% | 0.38+153.3% | 0.31+121.4% | 0.18+20.0% | 0.14-6.7% | 0.150.0% |
| Other Funds (Non Cash) | -0.02-105.9% | 0.81+153.1% | -0.05-183.3% | 0.06-60.0% | 0.34+17.2% | 0.32+6.7% | 0.06-87.0% | 0.15 |
| Funds from Operations | -5.03 | -6.49 | -6.57 | -4.96 | -4.37 | -3.37 | -2.62 | -2.32 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 1.88+116.1% | 0.48 | 2.75 | 0.80 | 0.87 | -0.43-153.8% | -0.32-135.2% | -1.86-362.0% |
| Cash from Operating Activities | -3.15 | -6.01 | -3.81 | -4.16 | -3.49 | -3.80 | -2.94 | -4.19 |
| Capital Expenditures | -0.42 | -0.02 | -1.53 | 0.08 | -0.77 | -0.12 | -0.17 | -0.19 |
| Net Assets From Acquisitions | 0.00 | 0.00 | -0.05 | 0.00 | -5.13 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.42 | -0.02 | -1.58 | 0.08 | -5.91 | -0.12 | -0.17 | -0.19 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 2.43+33.5% | 5.13 | 2.80-8.2% | 3.29-13.2% | 1.82-75.4% | 0.00-100.0% | 3.05-14.6% | 3.79 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 2.43+33.5% | 5.13 | 2.80-8.2% | 3.29-13.2% | 1.82-75.4% | 0.00-100.0% | 3.05-14.6% | 3.79 |
| Proceedsfrom Stock Options | -1.13 | 4.49 | 3.63-50.6% | 3.29 | -0.49 | 0.00 | 7.35 | -0.51 |
| Issuance or Reduction of Debt, Net | 0.80-91.7% | 0.98 | 1.53 | -0.53 | 9.64 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.80-91.7% | 0.98 | 1.53 | -0.53 | 9.64 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 1.62-83.2% | 1.40 | 1.45 | -0.42 | 9.64 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -0.83 | -0.42 | 0.09 | -0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 3.23-71.8% | 6.11 | 4.33+42.0% | 2.76-27.2% | 11.46+54.9% | 0.00-100.0% | 3.05-14.6% | 3.79 |
| Net Change in Cash | -0.34-116.5% | 0.08 | -1.06 | -1.31 | 2.06-52.0% | -3.92-504.1% | -0.05-107.6% | -0.59 |
| Free Cash Flow | -3.56 | -6.03 | -5.34 | -4.08 | -4.26 | -3.92 | -3.10 | -4.38 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Product | 7.87 | 6.49 | -17.6% | 37.2% |
| Service | 7.16 | 10.96 | +53.1% | 62.8% |
| Total | 15.03 | 17.44 | +16.0% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 15.03 | 17.44 | +16.0% | 100.0% |
| Total | 15.03 | 17.44 | +16.0% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 11.26% | 3.1M | 27.3M | 14.81M |
| 2026-10-15 | 8.65% | 2.4M | 27.3M | 12.72M |
| 2026-09-30 | 10.51% | 2.9M | 27.3M | 12.51M |
| 2026-09-15 | 5.97% | 1.6M | 27.3M | 11.55M |
| 2026-08-31 | 15.35% | 2.5M | 16.3M | 11.14M |
| 2026-08-14 | 9.98% | 1.2M | 12.5M | 2.49M |
| 2026-07-31 | 11.49% | 1.2M | 10.5M | 1.62M |
| 2026-07-15 | 11.51% | 1.2M | 10.5M | 1.68M |
| 2026-06-30 | 11.46% | 1.2M | 10.3M | 1.69M |
| 2026-06-15 | 9.24% | 0.9M | 10.3M | 1.42M |
| 2026-05-29 | 7.76% | 0.8M | 10.1M | 225.13K |
| 2026-05-15 | 9.65% | 1.0M | 10.1M | 213.51K |
| 2026-04-30 | 7.20% | 0.7M | 9.9M | 210.48K |
| 2026-04-15 | 6.30% | 0.6M | 8.8M | 175.04K |
| 2026-03-31 | 3.99% | 0.3M | 7.9M | 126.74K |
| 2026-03-13 | 6.11% | 0.5M | 7.9M | 124.49K |
| 2026-02-27 | 6.04% | 0.5M | 7.9M | 126.08K |
| 2026-02-13 | 6.51% | 0.5M | 7.2M | 132.22K |
| 2026-01-30 | 6.57% | 0.5M | 7.0M | 129.86K |
| 2026-01-15 | 5.91% | 0.4M | 7.0M | 153.25K |
Option chain
expiry 2026-11-13| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-02 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-10-29 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-10-29 | SEC |
| 2026-10-27 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-10-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-10-21 | PRER14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-10-21 | 8-K | Current report | 2026-10-20 | SEC |
| 2026-10-19 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-10-19 | SEC |
| 2026-10-19 | 8-K | Current report | 2026-10-15 | SEC |
| 2026-10-15 | 8-K | Current report | 2026-10-14 | SEC |
| 2026-10-01 | 8-K | Current report | 2026-09-29 | SEC |
| 2026-09-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-09-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-09-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-09-08 | 8-K/A | 2026-09-02 | SEC | |
| 2026-09-08 | 8-K | Current report | 2026-08-31 | SEC |
| 2026-09-03 | SCHEDULE 13G/A | SEC | ||
| 2026-08-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-31 | SEC |
| 2026-08-21 | 8-K | Current report | 2026-08-20 | SEC |
| 2026-08-14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-11 | SCHEDULE 13G | SEC | ||
| 2026-08-11 | 8-K | Current report | 2026-08-05 | SEC |
| 2026-08-03 | 8-K | Current report | 2026-07-31 | SEC |
| 2026-07-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-07-15 | 3 | Initial statement of beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-07-15 | SCHEDULE 13D | SEC | ||
| 2026-07-07 | 8-K | Current report | 2026-07-07 | SEC |
| 2026-06-25 | 8-K | Current report | 2026-06-25 | SEC |
| 2026-06-16 | 8-K | Current report | 2026-06-16 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 1.81M | 1 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| RAYMOND JAMES FINANCIAL INC | 1.04% |
| IHT Wealth Management, LLC | 0.55% |
| UBS Group AG | 0.45% |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.44% |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.31% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.25% |
| BlackRock, Inc. | 0.20% |
| Sequoia Financial Advisors, LLC | 0.17% |
| VANGUARD FIDUCIARY TRUST CO | 0.17% |
| NORTHERN TRUST CORP | 0.15% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND | 0.44% |
| Fidelity Extended Market Index Fund | 0.30% |
| Fidelity Total Market Index Fund | 0.06% |
| Fidelity Series Total Market Index Fund | 0.04% |
| Blackstone Alternative Multi-Strategy Fund | -0.03% |
OakChart. VVOS. Cached 15 minutes. Terms
Some panels did not load: ratings.